Applying Glycobiology To Develop Novel Medicines
About
IHP Therapeutics is developing a novel pipeline of glycan therapeutics targeting immune modulation/ inflammation and infection. IHP’s clinical-stage compound, IHP-009, is a glycan NCE (New Chemical Entity) with anticoagulant, anti-inflammatory and antiviral activity. Clinical planning is currently underway for dosing hospitalized COVID-19 patients with IHP-009.
Mission
To improve and save lives through scientific discovery and development of glycan therapeutics.
Our Team
Rinko Ghosh, MS, MBA
CEO
Jocelyn Jackson
Acting CFO
Peggy McLaughlin
VP of Clinical Operations
Gabriel Njikang, PhD
Director of CMC Project Mgmt
John Paderi, PhD
Chief Science Officer
Kate Stuart, PhD
VP of Program Management
Robert Van Gorp
VP of Strategic Sourcing
Board of Directors
Rinko Ghosh, MS, MBA
Vlad Hogenhuis, MD, MBA
John Paderi, PhD
Clinical and Scientific Advisors
Science
IHP Therapeutics is building on nearly a century of clinical and basic science research with glycan-based compounds to create the next generation of glyco-medicines to treat diseases with significant unmet need. We are developing both novel pipeline compounds as well as clinical-stage drugs like IHP-009, a new chemical entity with an established clinical safety profile. Our goal is to translate the therapeutic potential of these glycan compounds into clinically significant benefits for patients.